A Rare Disease Reveals a Hidden Flaw in the Immune System
What Happened?
Researchers at the Garvan Institute have discovered a malfunction in natural killer cells linked to mevalonate kinase deficiency (MKD), challenging decades of understanding about the disease.
Key points
- Mevalonate kinase deficiency (MKD) causes severe inflammatory episodes.
- Natural killer (NK) cells malfunction in MKD patients, leading to excessive inflammation.
- Existing treatments focus on macrophages, but many patients do not respond.
- Research indicates NK cell dysfunction is central to MKD.
- Baricitinib, a JAK inhibitor, showed promise in treating a severely affected infant.
Key insights
- This discovery could redefine treatment approaches for MKD and similar disorders.
- Understanding NK cell dysfunction may lead to better diagnostic methods for related genetic diseases.
- The findings may prompt further research into JAK inhibitors for other inflammatory conditions.
Why it matters
The findings could lead to new treatment options for patients with MKD who currently lack effective therapies.
Tags
Entities
Source
Science Daily

